Secretory breast cancer: mastectomy and radiotherapy to no evidence of disease

This breast cancer diagnosis at a glance

Stage at diagnosis
Stage II
Biomarkers
ER-negative; PR-negative; HER2-negative (triple-negative); Ki-67 50%; tumor-infiltrating lymphocytes 60%
Sex
Female
Treatment
surgery and radiation
Outcome
Cancer-Free / NED

Treatment course, step by step

  1. Right mastectomy with ipsilateral axillary lymphadenectomy [22-mm secretory carcinoma, pT2N0M0, 12 non-metastatic lymph nodes]
  2. no adjuvant chemotherapy recommended
  3. external hypofractionated 3D conformal radiotherapy to right chest wall, 42 Gy in 15 fractions of 2.8 Gy over 18 days [good tolerance; no clinical or radiologic relapse at 6 months].

What happened, in summary

A 65-year-old postmenopausal woman sought care for a painless right-breast mass she had noticed during self-examination 5 months earlier. She had no personal or family history of breast cancer. Examination found a hard 3.5 cm mass at the junction of the superior external quadrant and retro-areolar area, plus a mobile right axillary lymph node measuring 1.5 cm. Mammography and ultrasound showed an irregular right-breast mass and axillary adenopathy, classified as BI-RADS 5. Tru-Cut biopsy first suggested SBR grade 2 infiltrating ductal carcinoma. CT of the chest, abdomen, and pelvis showed no distant metastases. She underwent right mastectomy with ipsilateral axillary lymphadenectomy. Final pathology refined the diagnosis to infiltrating secretory-type breast carcinoma, measuring 22 mm, SBR grade 2. There were no vascular emboli or perineural invasion. A high-grade in situ component with multifocal comedo necrosis made up 10% of the tumor, and tumor-infiltrating lymphocytes were estimated at 60%. The nipple and skin were not involved, there was no Paget disease, and all 12 removed axillary lymph nodes were non-metastatic. Immunohistochemistry was negative for estrogen receptor, progesterone receptor, and HER2, confirming a triple-negative subtype; Ki-67 was 50%. The final classification was pT2N0M0. A multidisciplinary team recommended adjuvant radiation without chemotherapy. She received hypofractionated 3D conformal radiotherapy to the right chest wall, 42 Gy in 15 fractions over 18 days, with good tolerance and no significant side effects. As of May 2024, 6-month follow-up showed no clinical or radiologic evidence of relapse, and she remained on regular clinical surveillance afterward in follow-up clinic.

Where this story comes from

This is a lay summary of an account first published by PMC / PubMed Central. Read the original in full

How we source and attribute stories Accuracy and limitations

Collections this story belongs to

Similar breast cancer stories

These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer

Search more breast cancer stories